Anaphylaxis Checklists

ASCIA has developed the following five checklists to assist in the management of patients who are at risk of severe allergic reactions (anaphylaxis).

Anaphylaxis Checklist for Adrenaline Prescribers Updated January 2023

Anaphylaxis Checklist for Pharmacists Updated January 2023

Anaphylaxis Checklist for Patients Updated January 2023

Updated August 2020

Anaphylaxis Checklist for Prescribers of Adrenaline (Epinephrine) Injectors

The aim of this checklist is to assist doctors and nurse practitioners who prescribe adrenaline injectors for patients who are at risk of having a severe allergic reaction (anaphylaxis).

pdfAnaphylaxis Checklist for Prescribers of Adrenaline (Epinephrine) Injectors138.65 KB  

There are two brands of adrenaline injectors, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are available in Australia on the PBS, and New Zealand (Pharmac listed since 1 February 2023).
  • Anapen® 500, Anapen® 300 and Anapen® 150 are available in Australia on the PBS .

Adrenaline injectors are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.
  • Record history of the allergic reaction and suspected triggers using the ASCIA event record form 
  • Prescribe adrenaline injector and check that the dose is appropriate (see above).
  • Check that the prescription is for two devices, which are rebated by the PBS in Australia and Pharmac in New Zealand.
  • For newly diagnosed patients contact a specialist (allergy, respiratory, paediatrician), if necessary, for authority prescription, pending specialist appointment and inform patient/carer about patient and carer support organisations, Allergy & Anaphylaxis Australia or Allergy New Zealand 
  • Ensure that the patient has been referred to a clinical immunology/allergy specialist, who is listed on the ASCIA website.
  • Complete and sign ASCIA Action Plan for Anaphylaxis (RED) - the latest version is on the ASCIA website 
  • Complete ASCIA Travel Plan if required. 
  • Inform patient that they should always carry their adrenaline injector/s and ASCIA Action Plan.
  • Ensure the patient/carer understands that that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  • Educate patient/carer on how to give the adrenaline injector (using trainer devices), recognition and treatment of allergic reactions, carrying and storage of the adrenaline injector and appropriate allergen avoidance measures. For information go to
  • If patient has asthma, review and optimise asthma management and educate about asthma and anaphylaxis.
  • Inform patient/carer to check and note the expiry date of their injector/s.
  • Encourage an appointment every 12 to 18 months, to prescribe new adrenaline injector/s before they expire, to review if new allergies have developed or more severe allergic reactions have occurred, and to renew the patient’s ASCIA Action Plan for Anaphylaxis.

For adrenaline injector supply updates check

© ASCIA 2023

Content updated January 2023 

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.


Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia